More recently, in the phase III KATHERINE trial, T‐DM1 has been shown to improve invasive disease‐free survival (IDFS) in patients with early HER2+ BC that presented with residual invasive disease after neoadjuvant treatment with trastuzumab and taxanes.112. Here, ERBB2 is linked to breast cancer.